Press Release
Zydus receives final approval from the USFDA for Tranexamic Acid Injection19-07-2017
Real innovation will now happen in East and move to West'
Zydus Cadila's newly appointed chief sees bio-similars, biologics and vaccines critical for revenue generation, growthCut-Off Date For Twenty Second Annual General Meeting Scheduled To Be Held On Friday, August 11, 2017 At 1.00 P.M.
The Cut-Off Date for determining the eligibility of the members entitled to vote by electronic means and at the venue of Twenty Second Annual General Meeting scheduled to be held on Friday, August 11, 2017 at 1.00 p.m. The members holding shares as on the cut-off date will be entitled to exercise their voting rights electronically or at the venue of the Annual General Meeting.Intimation Of Meeting Of Board Of Directors And Closure Of Trading Windows.
In compliance with the provisions of Regulation 29 of the SEBI (Listing Obligations and Disclosures Requirements) Regulation 2015, we hereby inform that the meeting of the Board of Directors of the Company will be held on Friday, the August 11, 2017 to consider, inter alia, approve the unaudited financial results for the quarter ended on June 30, 2017....Press Release
'Zydus receives Tentative Approval from the USFDA for Fingolimod Capsules'.'Some gaps in the emerging markets portfolio, but not very significant'
Pankaj R Patel is passing on the baton of Zydus Cadila to his 38-year-old son Sharvil PatelStatement Of Complaints As On 30.06.2017.
In compliance with the provisions of Regulation 13 (3) of the SEBI Regulations 2015, the status of complaints are attached.Pankaj Patel steps down as Cadila MD, son to take over
Board of Directors of Cadila Healthcare has unanimously approved the appointment of Sharvil P Patel